Previous 10 | Next 10 |
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreem...
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed (PAVM) -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics (ONTX) -15%, elect...
Pandion Therapeutics shares rise ([[PAND]] +6.8%) after it presented preclinical data on PT001, the company’s tissue-tethered PD-1 agonist, at the Network for Pancreatic Organ Donors with Diabetes ((nPOD)) 13th Annual Scientific Meeting.The research, done in collaboration wit...
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today presented preclinical data on PT001, the...
WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief...
Pandion has a unique technology platform that can enable template-like design of protein therapeutics to treat autoimmunity. This platform has already attracted a large partnership with Astellas and has the potential to do similar deals overtime as Pandion's lead asset, PT101, is clin...
Looking For The Best Biotech Stocks To Watch This Week? 3 Names To Know Biotech stocks were some of the top performers on the stock market throughout 2020. With the coronavirus vaccine tailwind carrying over to 2021, investors still have their eyes peeled on the industry. Ri...
Gainers: Check-Cap (CHEK) +185%.Bionano Genomics (BNGO) +99%.The9 (NCTY) +92%.Ocugen (OCGN) +74%.Jaguar Health (JAGX) +42%.Pandion Therapeutics (PAND) +37%.ViewRay (VRAY) +33%.Bit Digital (BTBT) +29%.AirNet Technology (ANTE) +18%.Studio City International (MSC) +18%.Losers: ...
Pandion Therapeutics ([[PAND]] +22.2%) has announced top-line data from its Phase 1a single-dose, healthy volunteer trial, demonstrating proof of mechanism of PT101, in development for ulcerative colitis ((UC)), systemic lupus erythematosus ((SLE)), and other autoimmune diseases.PT101, a...
-Phase 1a trial achieved primary objective of safety and tolerability -PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases -PT101 maintained sele...
News, Short Squeeze, Breakout and More Instantly...
Pandion Therapeutics Inc. Company Name:
PAND Stock Symbol:
NASDAQ Market:
Best Biotech Stocks To Buy [Or Sell] Right Now Investors looking for high returns could turn to biotech stocks . These stocks are more volatile than your usual pick. However, could this be the right time to buy biotech stocks after rising Treasury yields continue to spark a tech...
Merck (NYSE: MRK) and Pandion Therapeutics, Inc. (NASDAQ: PAND) have reported entry into a definitive agreement where Merck will acquire Pandion for USD 60 per share in cash or a total equity value of USD 1.85 Billion. “This acquisition builds upon Merck...
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreem...